Literature DB >> 17465297

Simultaneous ovarian and endometrial osseous metaplasia: a case report.

Sebastiano Campo1, Vincenzo Campo, Gian Franco Zannoni, Pietro Gambadauro.   

Abstract

BACKGROUND: Endometrial ossification is a rare disease. More than 80% of cases occur after pregnancy, but it has been observed in patients with a history of endometritis, dilation and curettage, and metabolic disorders. CASE: A 42-year-old woman presented with osseous metaplasia of both the endometrium and ovaries. At laparoscopy both adnexa were covered with adhesions and were adherent to the posterior wall of the uterus. Following adhesiolysis, calcified nodules were removed from both ovaries with biopsy forceps. Endometrial bone tissue was removed by hysteroscopic resection.
CONCLUSION: To our knowledge, this is the first reported case of osseous metaplasia of both the endometrium and ovaries since all cases described to date in the literature involved only the uterine cavity. Conservative management with endoscopic surgery is effective.

Entities:  

Mesh:

Year:  2007        PMID: 17465297

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  4 in total

1.  Osseous Metaplasia of the Endometrium: A Rare Entity.

Authors:  Chandrakala Magudapathi; Radha Anathakrishnan; Harika Kalargala
Journal:  J Obstet Gynaecol India       Date:  2014-07-29

2.  Endometrial osseous metaplasia-a rare presentation of polymenorrhagia: a case report.

Authors:  Asma Nigar; Yogesh Kumar Yadav; Seema Hakim
Journal:  J Clin Diagn Res       Date:  2015-04-01

3.  Endometrial osseous metaplasia: Clinicopathological study of a case and literature review.

Authors:  T Umashankar; Shobhana Patted; Rs Handigund
Journal:  J Hum Reprod Sci       Date:  2010-05

4.  Simultaneous osseous metaplasia nodules of the submucosa and mesosalpinx after first trimester abortion: a case report.

Authors:  Zhou Feng; Qin Jiale; Zhang Xiaofei; Guo Qingyun; Huang Lili
Journal:  Eur J Med Res       Date:  2013-11-19       Impact factor: 2.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.